Table 2.
Inclusion of Essential Medicines in Family Planning and Abortion Guidelines, by Country
| Essential Medicines for Contraception and Medical Abortion (MA) in National Family Planning and/or Abortion Care Guidelines or Protocols | AFGHANISTAN | IRAQ | LEBANON | LIBYA | MOROCCO | oPt | PAKISTAN | SOMALIA | Total No. of Countries |
|---|---|---|---|---|---|---|---|---|---|
| Oral Hormonal Contraceptives | |||||||||
| Ethinylestradiol (30ug) + levonorgestrel (150 ug) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 8 |
| Ethinylestradiol (35ug) + norethisterone (1 mg) | ✓ | ✓ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | 7 |
| Injectables | |||||||||
| Medroxyprogesterone acetate IM/SC injection | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 8 |
| Estradiol cypionate + medroxyprogesterone acetate (5-25 mg) inj | ✓ | ✗ | ✓ | ✓ | ✗ | ✗ | ✓ | ✓ | 5 |
| Norethisterone enantate: 200 mg/ mL in 1- mL ampoule | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 8 |
| Implants | |||||||||
| Levonogestrel releasing implant: 150 mg | ✓ | ✓ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | 7 |
| Etonogestrel-releasing implant:68 mg | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 7 |
| IUDs | |||||||||
| Copper-containing IUD | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 8 |
| Levonogestrel-releasing IUD | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 8 |
| Vaginal Ring | |||||||||
| Progesterone-releasing vaginal ring | ✗ | ✓ | ✓ | ✓ | ✓ | ✗ | ✓ | ✗ | 5 |
| Emergency Contraceptives | |||||||||
| Ulipristal Tablet: 30 mg | ✗ | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | ✓ | 6 |
| Levonogestrel; 30 ug or 750 µg (pack of two); 1.5 mg | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 8 |
| MA Medicines | |||||||||
| Misoprostol—mifepristone combipack | ✓ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | 2 |
| Mifepristone | ✓ | ✗ | ✓ | ✗ | ✗ | ✗ | ✗ | ✗ | 2 |
| Misoprostol (either 400 μg or 600 μg, PO)/200mcg/25uga | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 8 |
| Total No. of Medicines | 12 | 12 | 15 | 12 | 10 | 11 | 13 | 12 | |
aMisoprostol often included in guidelines and EMLs for intrapartam care not abortion